CORE
🇺🇦
make metadata, not war
Services
Services overview
Explore all CORE services
Access to raw data
API
Dataset
FastSync
Content discovery
Recommender
Discovery
OAI identifiers
OAI Resolver
Managing content
Dashboard
Bespoke contracts
Consultancy services
Support us
Support us
Membership
Sponsorship
Community governance
Advisory Board
Board of supporters
Research network
About
About us
Our mission
Team
Blog
FAQs
Contact us
Allergen immunotherapy in MASK-air users in real-life: Results of a Bayesian mixed-effects model
Authors
B. Sousa-Pinto Azevedo, L.F. Sá-Sousa, A. Vieira, R.J. Amaral, R. Klimek, L. Czarlewski, W. Anto, J.M. Bedbrook, A. Kvedariene, V. Ventura, M.T. Ansotegui, I.J. Bergmann, K.-C. Brussino, L. Canonica, G.W. Cardona, V. Carreiro-Martins, P. Casale, T. Cecchi, L. Chivato, T. Chu, D.K. Cingi, C. Costa, E.M. Cruz, A.A. De Feo, G. Devillier, P. Fokkens, W.J. Gaga, M. Gemicioğlu, B. Haahtela, T. Ivancevich, J.C. Ispayeva, Z. Jutel, M. Kuna, P. Kaidashev, I. Kraxner, H. Larenas-Linnemann, D.E. Laune, D. Lipworth, B. Louis, R. Makris, M. Monti, R. Morais-Almeida, M. Mösges, R. Mullol, J. Odemyr, M. Okamoto, Y. Papadopoulos, N.G. Patella, V. Pham-Thi, N. Regateiro, F.S. Reitsma, S. Rouadi, P.W. Samolinski, B. Sova, M. Todo-Bom, A. Taborda-Barata, L. Tomazic, P.V. Toppila-Salmi, S. Sastre, J. Tsiligianni, I. Valiulis, A. Wallace, D. Waserman, S. Yorgancioglu, A. Zidarn, M. Zuberbier, T. Fonseca, J.A. Bousquet, J. Pfaar, O.
Publication date
1 January 2022
Publisher
Abstract
Background: Evidence regarding the effectiveness of allergen immunotherapy (AIT) on allergic rhinitis has been provided mostly by randomised controlled trials, with little data from real-life studies. Objective: To compare the reported control of allergic rhinitis symptoms in three groups of users of the MASK-air® app: those receiving sublingual AIT (SLIT), those receiving subcutaneous AIT (SCIT), and those receiving no AIT. Methods: We assessed the MASK-air® data of European users with self-reported grass pollen allergy, comparing the data reported by patients receiving SLIT, SCIT and no AIT. Outcome variables included the daily impact of allergy symptoms globally and on work (measured by visual analogue scales—VASs), and a combined symptom-medication score (CSMS). We applied Bayesian mixed-effects models, with clustering by patient, country and pollen season. Results: We analysed a total of 42,756 days from 1,093 grass allergy patients, including 18,479 days of users under AIT. Compared to no AIT, SCIT was associated with similar VAS levels and CSMS. Compared to no AIT, SLIT-tablet was associated with lower values of VAS global allergy symptoms (average difference = 7.5 units out of 100; 95% credible interval [95%CrI] = −12.1;−2.8), lower VAS Work (average difference = 5.0; 95%CrI = −8.5;−1.5), and a lower CSMS (average difference = 3.7; 95%CrI = −9.3;2.2). When compared to SCIT, SLIT-tablet was associated with lower VAS global allergy symptoms (average difference = 10.2; 95%CrI = −17.2;−2.8), lower VAS Work (average difference = 7.8; 95%CrI = −15.1;0.2), and a lower CSMS (average difference = 9.3; 95%CrI = −18.5;0.2). Conclusion: In patients with grass pollen allergy, SLIT-tablet, when compared to no AIT and to SCIT, is associated with lower reported symptom severity. Future longitudinal studies following internationally-harmonised standards for performing and reporting real-world data in AIT are needed to better understand its ‘real-world’ effectiveness. © 2022 The Authors. Clinical and Translational Allergy published by John Wiley & Sons Ltd on behalf of European Academy of Allergy and Clinical Immunology
Similar works
Full text
Available Versions
Pergamos : Unified Institutional Repository / Digital Library Platform of the National and Kapodistrian University of Athens
See this paper in CORE
Go to the repository landing page
Download from data provider
oai:lib.uoa.gr:uoadl:3219871
Last time updated on 10/02/2023